膀胱腫瘍患者におけるADCC活性について

Abstract

(1) microplate法によるADCC活性の測定に関し基礎的検討をおこなった.1)抗体濃度は30～80 μg/mlで至適と考えられた.2) 250～4000 cells/mlの低リンパ球数でも一定したplaque-forming cellsの割合が得られた.3) incubation timeは2時間以上が必要と考えられた.以上の結果より, plaque-forming cellsの割合の検討には抗体濃度50 μg/ml, リンパ球数2×106 cells/ml, incubation time 3時間という条件にて, リンパ球中のK cellの割合を同定した.(2)膀胱腫瘍患者14例, 泌尿器科的良性症患患者7例および健常人6例についてK cellの割合を測定した.膀胱腫瘍患者のK cellの割合の平均は, 対照群に比し有意に低下していた.深達度別検討でもhigh stage群はlow stage群, 泌尿器科的良性疾患患者および健常人に比し有意に低下していた.膀胱腫瘍患者11例について, 手術前後のK cellの割合の変動を検討したが, low stage群, high stage群とも一定の傾向は認められなかった

K cell population, a parameter of antibody dependent cell-mediated cytotoxicity CADCC) activity, was determined in patients with urinary bladder cancer, urological benign diseases and in normal subjects by the microplate technique using an antibody concentration of 50 flg/ml, lymphocyte concentration of 2 X 106 cells/ml and incubation time of 3 hours. The K cell population of peripheral lymphoyctes was 4.7 ± 2.0 % in 14 patients with urinary bladder cancer, 6.7 ±2.0% in 7 patients with urologinal benign disease and 7.5± 1.5% in 6 normal subjects. The K cell population in patients with high stage bladder cancer was significantly higher than those with low stage cancer. The K cell population in both high and low stages bladder cancer was not changed after removal of the tumor. ADCC activity did not reflect the immune state of cancer patients during the pre- and postoperative courses.